David C. Myles sold $1.6M of OLMA
CH. DISCOV. & NON-CLIN DEV OFF at Olema Pharmaceuticals, Inc.. 51,000 shares at an average of $30.46, traded Dec 19, 2025, filed Dec 23, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.6M at market
- 0Share of holdings soldSold 8.5% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.5%, 3m -49.7%, 6m -61.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001831216-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | SOpen-market sale Common Stock | -1,225 | $28.08 | $34k | 601,656 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock | -43,729 | $30.40 | $1.3M | 557,927 | Dec 23, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stock | -6,046 | $31.39 | $190k | 551,881 | Dec 23, 2025 |
| Dec 19, 2025 | GGift Common Stock | -9,000 | $0.00 | $0 | 542,881 | Dec 23, 2025 |
Related signals
Other insiders at Olema Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $291k 25,000 shares | -3% | |
| 44Moderate | OLMAsell Olema Pharmaceuticals, Inc. | Shawnte Mitchell CHIEF LEGAL OFFICER | $952k 40,000 shares | -267% | |
| 43Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $269k 10,000 shares | -1% | |
| 40Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $102k 3,489 shares | -0% | |
| 65Notable | Olema Pharmaceuticals, Inc. | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | $3.0M 103,822 shares | -43% | |
| 60Notable | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $3.1M 110,000 shares | -71% | |
| 39Weak | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $82k 2,881 shares | -0% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Ian T Clark director | $7.9M 264,800 shares | -100% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Naseem Zojwalla Chief Medical Officer | $7.5M 269,509 shares | -155% | |
| 27Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $205k 25,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.